Takeda to commercialize Xenon pain product in Asia

Under terms of the agreement, Takeda is responsible for all development and commercialization activities in the licensed territories. Xenon will receive an upfront cash payment of up to $75.5 million and is eligible to receive milestone payments upon successful commercialization of XEN401. Takeda will pay Xenon royalties on all product sales.

“There is a genuine need for improved pain treatments and such treatments are strategically linked to Takeda's core therapeutic areas including diabetes, oncology, and bone/joint disease,” said Yasuchika Hasegawa, president of Takeda.

Takeda has entered the agreement in order to increase the number of products in its development pipeline, as patents on four of its major products are due to end in the next few years.

XEN401 is currently in preclinical development.